STOCK TITAN

[SCHEDULE 13G] Bicara Therapeutics Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reported a passive ownership stake in Bicara Therapeutics Inc. common stock. The firm beneficially owns 3,236,595 shares, representing 5.9% of the outstanding common stock as of December 31, 2025.

T. Rowe Price has sole power to vote and dispose of these 3,236,595 shares and no shared voting or dispositive power. The firm certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Bicara Therapeutics.

Positive

  • None.

Negative

  • None.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:02/17/2026